2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-169813
    Yakuchinone B 81840-57-5 98%
    Yakuchinone B is an Acyl-CoA: cholesterol O-acyltransferase (ACAT) inhibitor with hypocholesterolemic activity, which is found in the seeds of Zingiberaceae. Yakuchinone B inhibits rat hepatic ACAT with an IC50 value of 20.6 μM. Yakuchinone B is promising for research of hypercholesterolemia and atherosclerosis.
    Yakuchinone B
  • HY-169824
    TRPML modulator 1 2171065-77-1 98%
    TRPML modulator 1 (compound A12) is a TRPML modulator that promotes autophagy. TRPML modulator 1 AC50 in the TFEB test is less than 2 mM.
    TRPML modulator 1
  • HY-169827
    EMD-132338 167364-01-4 98%
    EMD-132338 is a GPIIb/IIIa (αIIbβ3) antagonist that inhibits platelet aggregation. EMD-132338 can be utilized in antithrombosis research.
    EMD-132338
  • HY-17003R
    Saquinavir mesylate (Standard) 149845-06-7
    Saquinavir mesylate (Standard) (Ro 31-8959/003 (Standard)) is the analytical standard of Saquinavir mesylate (HY-17003). This product is intended for research and analytical applications. Saquinavir (Ro 31-8959) mesylate is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir mesylate also has anti-inflammatory activity and can induce apoptosis of human red blood cells.
    Saquinavir mesylate (Standard)
  • HY-17005R
    Olmesartan medoxomil (Standard) 144689-63-4 99.68%
    Olmesartan medoxomil (Standard) is the analytical standard of Olmesartan medoxomil. This product is intended for research and analytical applications. Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC50 of 66.2 μM.
    Olmesartan medoxomil (Standard)
  • HY-17005S
    Olmesartan medoxomil-d6 1127298-67-2 98%
    Olmesartan medoxomil-d6 (CS 866-d6) is the deuterium labeled Olmesartan medoxomil. Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC50 of 66.2 μM.
    Olmesartan medoxomil-d6
  • HY-17007S
    Saquinavir-d9 1356355-11-7 98%
    Saquinavir-d9 (Ro 31-8959-d9) is the deuterium labeled Saquinavir (HY-17007). Saquinavir (Ro 31-8959) is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir also has anti-inflammatory activity and can induce apoptosis of human red blood cells.
    Saquinavir-d9
  • HY-170387
    MRS8209 98%
    MRS8209 is the antagonist for serotonin receptor with a Ki of 4.27 nM for 5-HT2BR. MRS8209 exhibits protective effect on pressure at airway opening (PAO), and can be used in research of pulmonary fibrosis.
    MRS8209
  • HY-170392
    Vasorelaxant agent-1 98%
    Vasorelaxant agent-1 (Compound 2j) is a BBB-penetrable vasodilator. Vasorelaxant agent-1 has excellent vasodilator activity with an EC50 of 0.02916 μM. Vasorelaxant agent-1 is non-carcinogenic and can be used in the study of hypertension.
    Vasorelaxant agent-1
  • HY-170419
    APJ receptor agonist 10 3037373-19-3 98%
    APJ receptor agonist 10 (Compound I choline salt) modulates the activity of APJ receptor and can be used in research about pulmonary arterial hypertension. APJ receptor agonist 10 exhibits good bioavailability other than its free base form.
    APJ receptor agonist 10
  • HY-170435
    PDE5-IN-13 98%
    PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC50 of 3 nM. PDE5-IN-13 is a potential candidate for PAH (pulmonary arterial hypertension) research. PDE5-IN-13 has high selectivity for targets over PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. PDE5-IN-13 is orally active.
    PDE5-IN-13
  • HY-170485
    Thrombin inhibitor 13 98%
    Thrombin inhibitor 13 (Compound 13a) is a covalent and reversible inhibitor for thrombin (FIIa) with an IC50 of 0.7 nM. Thrombin inhibitor 13 prolongs the activated partial thromboplastin time (aPTT) and prothrombin time (PT), exhibits antithrombotic and anticoagulant activities.
    Thrombin inhibitor 13
  • HY-170509
    Ferroptosis-IN-17 98%
    Ferroptosis-IN-17 (Compound 18) is a ferroptosis (Ferroptosis) inhibitor with an EC50 value of 0.57 μM. Ferroptosis-IN-17 reduces intracellular ferrous ion accumulation, lipid peroxidation, and effectively restores the levels of glutathione (GSH) and glutathione peroxidase 4 (GPX4). Ferroptosis-IN-17 shows good solubility and significant metabolic stability in rat plasma. Ferroptosis-IN-17 is promising for research in tumor suppression, neurodegenerative diseases, and cardiovascular diseases.
    Ferroptosis-IN-17
  • HY-170604
    MMP-2 Inhibitor-4 98%
    MMP-2 Inhibitor-4 (Compound 5g) is an MMP-2 inhibitor with an IC50 of 152.62 nM. MMP-2 Inhibitor-4 can reduce the levels of MMP-2 in the K562 cell line through stable binding at the MMP-2 active site, and it demonstrates strong antiangiogenic effects in the ACHN cell line. MMP-2 Inhibitor-4 holds promise for research in chronic myeloid leukemia (CML).
    MMP-2 Inhibitor-4
  • HY-170774
    Hypoxia inducer-1 98%
    Hypoxia inducer-1 (Compound N6) is an orally active hypoxia activated nitric oxide (NO) donor compound. Hypoxia inducer-1 exhibits highly selective NO release under hypoxic conditions and inhibits hypoxia-induced apoptosis, necrosis, and the increase in ROS levels. Hypoxia inducer-1 regulates vascular dilation and has a protective effect in a mouse model of myocardial hypoxia injury. Hypoxia inducer-1 can be used in the research of coronary heart disease.
    Hypoxia inducer-1
  • HY-170867
    Nrf2/HO-1 activator 3 98%
    Nrf2/HO-1 activator 3 (Compound C3a) is the activator for Nrf2 signaling pathway that promotes the Nrf2 translocation into nuclei and upregulates the expression of heme oxygenase-1 HO-1. Nrf2/HO-1 activator 3 inhibits the overespression of ROS and MDA in H2O2- or glucose-stimulated H9c2 cardiomyocytes, inhibits the cell viability and colony formation, thereby exhibiting antioxidant efficacy.
    Nrf2/HO-1 activator 3
  • HY-171049
    Androgen receptor modulator 3 1018971-95-3 98%
    Androgen receptor modulator 3 is a selective modulator for androgen receptor that can be used for research of sarcopenia.
    Androgen receptor modulator 3
  • HY-171241
    Imolamine 318-23-0 98%
    Imolamine is a potent antiplatelet aggregation agent, is a phenyl aminoxidiazole derivative. Imolamine has the potential for the research of coronary heart disease.
    Imolamine
  • HY-171249
    CDD-1431 3034216-31-1 98%
    CDD-1431 is a low-nanomolar selective kinase inhibitors of BMPR2, with Kiapp value of 20.6 nM. CDD-1431 suppresses BRE-reporter activity, with an IC50 of 4.87 μM. BMP controls cellular processes across many tissue types, including the kidney, skeletal muscle, heart, and reproductive organs. BMP induces ectopic bone formation.
    CDD-1431
  • HY-171461
    CGS 24592 147923-04-4 98%
    CGS 24592 is an orally active, selective and potent neutral endopeptidase 24.11 (NEP) inhibitor with an IC50 value of 1.6 nmol/L. CGS 24592 reduces the degradation of atrial natriuretic peptide (ANP), increases the concentration of ANP in the plasma, and reduces blood pressure. CGS 24592 is promising for research of cardiovascular disease, such as hypertension and congestive heart failure.
    CGS 24592
Cat. No. Product Name / Synonyms Application Reactivity